

Key Antibodies For










Ovarian Cancer




Ovarian cancers are a relatively rare diagnosed cancer in the United States, with about 1.3% of new cancer cases classified as ovarian yet contributing approx. 2.4% of cancer deaths yearly. As of 2013, there were approximately 196,000 women living with ovarian cancer in the United States. Those diagnosed with ovarian cancer have a 5 year survival rate of 46.2%. Over the last 10 years, both the new cancer case rate and the death rate have dropped 1.9% and 2.2% per year, respectively. Biocare Medical is proud to offer key ovarian antibodies that may aid in the identification of their respective proteins by IHC in FFPE tissues.

SEER Cancer Statistics Factsheets: Ovary Cancer. National Cancer Institute. Bethesda, MD, <http://seer.cancer.gov/statfacts/html/ovary.html>

Key Antibodies for Ovarian Cancer


Product Name	Source	Clone	Catalog Number
PAX8 (M)		BC12	ACI 438; API 438; OAI 438; AVI 438
CDH17 (M)		1H3	ACI 3111; API 3111; AVI 3111
CDX2 + CK7		CDX2-88 + BC1	PM 367DS
CD99		EP8	CME 392; PME 392; OAI 392
CA 125		OC125	CM 101; PM 101
Cytokeratin 7 (CK7)		BC1	CRM 339; PRM 339; IP 339
CDX2 (RM)		EP25	ACI 3144; API 3144
Human Chorionic Gonadotropin (Beta)		Polyclonal	CP 124; PP 124
CD103 (RM)		EP206	ACI 3117; API 3117

Key Antibodies for Ovarian Cancer




PAX8 (M)

PAX8 is expressed in a majority of renal cell and ovarian cancers. PAX8 [BC12] does not stain B-cells, cells of pancreatic origin and neuroendocrine cells in stomach and colon. It also does not recognize PAX2, PAX5 or PAX6 proteins. US Patent 8,852,592 and patents pending.




CDH17 (M)

CDH17 antibody (Cadherin 17 or LI-cadherin) is a highly specific marker in colon cancer and is a more sensitive marker than CDX2 and CK20. Overexpression of CDH17 (and conversely, underexpression of CDX2) correlates to poor prognosis in patients with epithelial ovarian cancer.




CDX2 + CK7

CDX2 + CK7 may distinguish colonic carcinomas metastatic to the ovaries from primary ovarian carcinomas. CDX2 is a sensitive marker for colonic carcinoma metastatic to the ovary. CK7 shows expression in primary ovarian tumors and metastases of upper gastrointestinal tract origin.




CD99

CD99 is expressed on the cell membrane of some lymphocytes, cortical thymocytes, and granulosa cells of the ovary. CD99 may be a sensitive marker for Ewing's sarcoma and peripheral neuroectodermal tumors and may aid in the differential diagnosis of small blue cell tumors.




CA 125

CA 125 reacts with epithelial ovarian neoplasms of serous, endometrioid, clear cell and undifferentiated types as well as normal tissues and neoplasms of fallopian tube, endocervix and mesothelioma. No reactivity has been shown for mucinous ovarian tumors, germ cell or hematopoietic tumors.




Cytokeratin 7 (CK7)

Cytokeratin 7 is expressed in epithelial cells of ovary, lung and breast. Often used with CK20 and CDX2 to aid in distinguishing pulmonary, ovarian and breast carcinomas (CK7+) from most colon carcinomas (CK7-). Clone BC1 is highly specific to CK7 and shows no cross-reaction with other IFPs.




CDX2 (RM)

CDX2 is a sensitive marker for colonic carcinoma metastatic to the ovary and is more specific than CK20. CDX2 is expressed in mucinous ovarian carcinomas but not in normal gastric mucosa. The rabbit monoclonal is more sensitive with fewer false negatives than mouse CDX2 clones.



Human Chorionic Gonadotropin (Beta)

Human chorionic gonadotropin (hCG) is a synthesized in syncytiotrophoblastic cells of placenta and in certain trophoblastic tumors. It labels the cytoplasm of syncytiotrophoblastic cells and their tumors, as well as germ cell tumors of the ovaries, testes and extragonadal sites.



CD103 (RM)

CD103 [EP206] has demonstrated reactivity in FFPE tissue, eliminating the need for flow cytometry or frozen section IHC. Intraepithelial CD8(+) tumor-infiltrating lymphocytes (TIL) that express CD103 have been shown to be strongly associated with patient survival in high-grade serous ovarian cancer.